Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
    Gijsen, M.
    King, P.
    Perera, T.
    Parker, P.
    Larijani, B.
    Harris, A.
    Kong, A.
    BREAST CANCER RESEARCH, 2010, 12 : S1 - S1
  • [2] UPREGULATION OF ADAM17 PROTEASE AND HER LIGANDS THROUGH A PKB NEGATIVE FEEDBACK LOOP MEDIATES ACQUIRED RESISTANCE TO TRASTUZUMAB IN HER2 OVEREXPRESSED BREAST CANCER
    Gijsen, M.
    King, P.
    Perera, T.
    Parker, P.
    Larijani, B.
    Kong, A.
    Harris, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 51 - 51
  • [3] Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
    Luque-Cabal, Maria
    Garcia-Teijido, Paula
    Fernandez-Perez, Yolanda
    Sanchez-Lorenzo, Luisa
    Palacio-Vazquez, Isabel
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 21 - 30
  • [4] HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
    Gajria, Devika
    Chandarlapaty, Sarat
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 263 - 275
  • [5] AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Sanz, F. Carmona
    Montemurro, F.
    Rossi, V.
    Verma, C.
    Berger, M.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 27 - 28
  • [6] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park
    Sun Kyoung Kang
    Woo Sun Kwon
    Inhye Jeong
    Tae Soo Kim
    Seo Young Yu
    Sang Woo Cho
    Hyun Cheol Chung
    Sun Young Rha
    Scientific Reports, 13
  • [8] Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells
    Yoshioka, Takahiro
    Shien, Kazuhiko
    Takeda, Tatsuaki
    Takahashi, Yuta
    Kurihara, Eisuke
    Ogoshi, Yusuke
    Namba, Kei
    Torigoe, Hidejiro
    Sato, Hiroki
    Tomida, Shuta
    Yamamoto, Hiromasa
    Soh, Junichi
    Fujiwara, Toshiyoshi
    Toyooka, Shinichi
    CANCER SCIENCE, 2019, 110 (08) : 2549 - 2557
  • [9] Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
    Junttila, Teemu T.
    Parsons, Kathryn
    Olsson, Christine
    Lu, Yanmei
    Xin, Yan
    Theriault, Julie
    Crocker, Lisa
    Pabonan, Oliver
    Baginski, Tomasz
    Meng, Gloria
    Totpal, Klara
    Kelley, Robert F.
    Sliwkowski, Mark X.
    CANCER RESEARCH, 2010, 70 (11) : 4481 - 4489
  • [10] Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
    Christina H. Yeon
    Mark D. Pegram
    Investigational New Drugs, 2005, 23 : 391 - 409
12345